American Oriental Bioengineering, Inc. (AOBI)

Market Cap	88.00 -100.0%
Revenue (ttm)	121.58M -10.2%
Net Income	-91.02M
EPS	-1,243.22
Shares Out	72.99K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	635
Open	0.0012
Previous Close	0.0011
Day's Range	0.0012 - 0.0012
52-Week Range	0.0011 - 0.0012
Beta	0.14
RSI	n/a
Earnings Date	n/a

About AOBI

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offe...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shujun Liu
• Employees: 3,719
• Stock Exchange: OTCMKTS
• Ticker Symbol: AOBI

Financial Performance

In 2012, AOBI's revenue was $145.10 million, a decrease of -31.78% compared to the previous year's $212.69 million. Losses were -$59.71 million, -11.47% less than in 2011.